The recent recall of Ranitidine by FDA has raised serious global concerns with respect to testing and quality of pharmaceutical products. In the past, NDMA and NDEA impurities were also reported in valsartan and sartans resulting in product recall by FDA and EMA.
This 30 Mins session will deliberate on ways to deal with these impurities in drug substances and drug products.